RxDoctor Payments Data

Rebecca Baker

Family · Alamo, TNNPI 1730418385

Payments from drug & device makers

$7,539in general payments, 2019–2025

Across 496 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$961
  • Lilly USA, LLC$766
  • AstraZeneca$463
  • Pfizer$391
  • Amgen$332
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$7,533100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,539 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,123
Medicare patients
29
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$57,582
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,391
VraylarCariprazine Hcl15$21,811
JardianceEmpagliflozin14$19,556
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,594
FarxigaDapagliflozin Propanediol12$8,469
LinzessLinaclotide11$7,748
EliquisApixaban11$6,712
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen149$3,824
Icosapent Ethyl13$2,113
Atorvastatin Calcium117$1,133
Omeprazole72$894
Albuterol Sulfate HfaAlbuterol Sulfate42$877
Gabapentin61$735
Levothyroxine Sodium65$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$961$57,58251 claims
AbbVieVraylar, Linzess$1,105$29,55926 claims
AstraZenecaBreztri Aerosphere, Farxiga$463$24,06337 claims
GSKTrelegy Ellipta$243$22,39131 claims
Boehringer IngelheimJardiance$189$19,55614 claims
PfizerEliquis$391$6,71211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Alamo

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →